Annexon, Inc. (NASDAQ:ANNX) Short Interest Update

Annexon, Inc. (NASDAQ:ANNX) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 8,980,000 shares, a growth of 23.7% from the December 15th total of 7,260,000 shares. Based on an average trading volume of 1,340,000 shares, the short-interest ratio is currently 6.7 days.

Analyst Ratings Changes

A number of research firms recently issued reports on ANNX. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon presently has a consensus rating of “Buy” and an average price target of $15.80.

Annexon Stock Up 2.2 %

NASDAQ:ANNX opened at $4.20 on Friday. The stock has a market cap of $447.68 million, a P/E ratio of -4.00 and a beta of 1.11. The business’s 50-day moving average price is $5.18 and its two-hundred day moving average price is $5.92. Annexon has a twelve month low of $3.86 and a twelve month high of $8.40.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. grew its stake in Annexon by 65.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 429,584 shares of the company’s stock worth $2,204,000 after buying an additional 170,180 shares in the last quarter. JPMorgan Chase & Co. grew its position in Annexon by 16.0% in the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after acquiring an additional 235,810 shares in the last quarter. Franklin Resources Inc. bought a new position in Annexon in the third quarter valued at $292,000. Barclays PLC raised its position in Annexon by 212.0% during the third quarter. Barclays PLC now owns 177,765 shares of the company’s stock valued at $1,052,000 after purchasing an additional 120,789 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Annexon by 18.3% during the third quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after purchasing an additional 331,269 shares during the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.